

# Ziping Wang

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1425429/ziping-wang-publications-by-year.pdf>

**Version:** 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32  
papers

201  
citations

8  
h-index

13  
g-index

42  
ext. papers

448  
ext. citations

4.5  
avg, IF

2.71  
L-index

#	Paper	IF	Citations
32	Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.. <i>Lancet Oncology, The</i> , <b>2022</b> ,	21.7	8
31	Significant Upregulation of HERV-K (HML-2) Transcription Levels in Human Lung Cancer and Cancer Cells.. <i>Frontiers in Microbiology</i> , <b>2022</b> , 13, 850444	5.7	1
30	Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting. <i>Journal of Thoracic Disease</i> , <b>2021</b> , 13, 1813-1821	2.6	0
29	Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study. <i>Frontiers in Molecular Biosciences</i> , <b>2021</b> , 8, 639892	5.6	5
28	Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients. <i>Annals of Translational Medicine</i> , <b>2021</b> , 9, 33	3.2	7
27	Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 981-994	4.4	4
26	Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I-IIIa non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , <b>2021</b> , 13, 1799-1812	2.6	0
25	Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 1959-1963	8.9	1
24	Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1617-1625	13.4	20
23	Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung.. <i>Thoracic Cancer</i> , <b>2021</b> ,	3.2	1
22	Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. <i>Cancer Cell International</i> , <b>2020</b> , 20, 590	6.4	
21	Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 1015-1026	8.9	25
20	Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 626	5.3	5
19	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 892-901	12.9	34
18	Characteristics and Outcomes of a Sample of Patients With COVID-19 Identified Through Social Media in Wuhan, China: Observational Study. <i>Journal of Medical Internet Research</i> , <b>2020</b> , 22, e20108	7.6	15
17	A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database. <i>BMC Cancer</i> , <b>2020</b> , 20, 666	4.8	8
16	Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1137	5.3	3

15	The adverse events associated with combination immunotherapy in cancers: Challenges and chances. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2020</b> , 16, e154-e159	1.9	3
14	Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis. <i>BMC Cancer</i> , <b>2020</b> , 20, 793	4.8	6
13	Characterization of Microbiota in Cancerous Lung and the Contralateral Non-Cancerous Lung Within Lung Cancer Patients. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1584	5.3	1
12	Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1193-1202	3.2	4
11	A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy. <i>Lung Cancer</i> , <b>2019</b> , 130, 135-142	5.9	5
10	Nomogram to predict cause-specific mortality in extensive-stage small cell lung cancer: A competing risk analysis. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1788-1797	3.2	5
9	Optimal first-line treatment for advanced thymic carcinoma. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 2081-2087	3.2	6
8	Survival comparison of right and left side non-small cell lung cancer in stage I-IIIa patients: A Surveillance Epidemiology and End Results (SEER) analysis. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 459-471	3.2	8
7	Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 291-297	3.2	4
6	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1166-1173	3.2	7
5	Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I-IIIa non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8524-8524	2.2	
4	Survival in right-sided versus left-sided stage IB-IIIa non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e20509-e20509	2.2	
3	Population-based study predicting the probability of death resulting from non-small cell lung cancer (NSCLC) and other causes among NSCLC patients with surgery.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 8525-8525	2.2	
2	Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study). <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1795-1800	3.2	2
1	Survival difference between Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2017</b> , 29, 553-560	3.8	10